Clinical trials: Iron Deficiency Anemia Treatment
Anemia, Iron-Deficiency
A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with…
- Trial name
- NCT02570854
- Testing
- CSJ137
- Where
- 13 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
The objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (IV) ferumoxytol with IV iron sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD.
- Trial name
- NCT01227616
- Testing
- Ferumoxytol, Iron Sucrose
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 296 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Iron Deficiency Anemia
A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
- Trial name
- NCT01114139
- Testing
- Ferumoxytol
- Where
- 182 sites in United States, Canada and 4 more
- Volunteers
- 812 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Anemia
Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients
This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.
- Trial name
- NCT00223964
- Testing
- Ferrlecit (sodium ferric gluconate complex in sucrose injection)
- Where
- 24 sites in United States, Mexico and 3 more
- Volunteers
- 59 people
- Sponsor
- Watson Pharmaceuticals
Iron Deficiency Anemia
Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia
The purpose of this study is to investigate the pharmacokinetics of serum iron (the amount of iron in blood) after single oral administration of 2 tablets of L0008 80 mg (as ferrous sulphate) in women with iron deficiency anaemia.
- Trial name
- NCT01757119
- Testing
- Tardyferon 80 mg
- Where
- 2 sites in Romania
- Volunteers
- 55 people
- Sponsor
- Pierre Fabre Medicament
Iron-Deficiency Anemia
Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy
Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of ferric carboxymaltose (FCM) in treatment of anaemia in subjects with multiple myeloma (MM) initiating chemotherapy.
- Trial name
- AOC-MM (NCT01100879)
- Testing
- Ferric carboxymaltose
- Where
- 2 sites in France, Greece
- Volunteers
- 3 people
- Sponsor
- Vifor Pharma
Anemia, Iron-Deficiency, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with…
- Conditions
- Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
- Trial name
- NCT02680756
- Testing
- Ferric Maltol, Ferric Carboxy Maltose
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 250 people
- Sponsor
- Shield Therapeutics
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
MOMENTUM is a randomized, double-blind, active control Phase 3 trial intended to confirm the differentiated clinical benefits of the investigational drug momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic…
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04173494
- Testing
- Momelotinib, Danazol
- Where
- 167 sites in United States, Australia and 20 more
- Volunteers
- 195 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Iron Deficiency Anaemia, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).
- Conditions
- Iron Deficiency Anaemia, Inflammatory Bowel Disease, Crohn's Disease
- Trial name
- AEGIS-2 (NCT01352221)
- Testing
- ST10
- Volunteers
- 128 people
- Sponsor
- Shield Therapeutics
Anaemia
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
The purpose of this study is to look at how well Ferric Carboxymaltose, an intravenous iron therapy (iron that is infused directly into your body through a vein), compares with ferrous sulphate capsules taken by mouth in the…
- Trial name
- ASAP (NCT01131624)
- Testing
- ferrous sulphate, Ferinject
- Where
- 20 sites in Australia, Germany and 3 more
- Volunteers
- 252 people
- Sponsor
- Vifor Pharma
Anemia of Chronic Kidney Disease
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects…
- Trial name
- NCT02268994
- Testing
- ferric citrate
- Where
- 36 sites in United States
- Volunteers
- 234 people
- Sponsor
- Keryx Biopharmaceuticals
Iron Deficiency, Anaemia
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in participants with iron deficiency anaemia under fasting condition.
- Trial name
- NCT06080555
- Testing
- Ferric Carboxymaltose Injection, Ferric Carboxymaltose Injection [Ferinject]
- Where
- 4 sites in China
- Volunteers
- 84 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
Study evaluating the efficacy and safety of intravenous (IV) ferumoxytol compared with oral iron for the treatment of pediatric participants with chronic kidney disease (CKD).
- Trial name
- NCT01155388
- Testing
- Ferumoxytol, Oral Iron
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Iron-Deficiency Anemia, Iron-Deficiency
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Real-CHOICE - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards IV (intravenous) iron therapy in general and IIM (iron isomaltoside…
- Trial name
- Real-CHOICE (NCT04318405)
- Testing
- Iron isomaltoside 1000
- Where
- 21 sites in Switzerland
- Volunteers
- 327 people
- Sponsor
- Pierre Fabre Pharma AG
Iron Deficiency, Anemia
A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
The purpose of the study is to evaluate the safety and efficacy of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA) in participants with chronic kidney disease (CKD).
- Conditions
- Iron Deficiency, Anemia, Kidney Disease
- Trial name
- FIRST (NCT01052779)
- Testing
- Ferumoxytol, Iron Sucrose
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 162 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Iron Deficiency Anemia
Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy
The main purpose is to determine whether FPC, administered via infusion, is safe and effective for the treatment of iron deficiency anemia (IDA) in patients receiving Home Infusion therapies (HI).
- Trial name
- NCT05110768
- Testing
- Triferic AVNU
- Volunteers
- 75 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Iron Deficiency Anemia
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with…
- Trial name
- NCT01264679
- Testing
- Ferumoxytol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- AMAG Pharmaceuticals, Inc.